| Literature DB >> 32331323 |
Miguel Angel Galan-Martin1,2, Federico Montero-Cuadrado1, Enrique Lluch-Girbes3,4,5, María Carmen Coca-López6, Agustín Mayo-Iscar7, Antonio Cuesta-Vargas8,9,10.
Abstract
Chronic musculoskeletal pain affects more than 20% of the population, leading to high health care overload and huge spending. The prevalence is increasing and negatively affects both physical and mental health, being one of the leading causes of disability. The most common location is the spine. Most treatments used in the Public Health Services are passive (pharmacological and invasive) and do not comply with current clinical guidelines, which recommend treating pain in primary care (PC) with education and exercise as the first-line treatments. A randomized multicentre clinical trial has been carried out in 12 PC centres. The experimental group (EG) conducted a program of pain neuroscience education (6 sessions, 10 h) and group physical exercise with playful, dual-tasking, and socialization-promoting components (18 sessions in 6 weeks, 18 h), and the control group performed the usual physiotherapy care performed in PC. The experimental treatment improved quality of life (d = 1.8 in physical component summary), catastrophism (d = 1.7), kinesiophobia (d = 1.8), central sensitization (d = 1.4), disability (d = 1.4), pain intensity (d = 3.3), and pressure pain thresholds (d = 2). Differences between the groups (p < 0.001) were clinically relevant in favour of the EG. Improvements post-intervention (week 11) were maintained at six months. The experimental treatment generates high levels of satisfaction.Entities:
Keywords: chronic pain; chronic spinal pain; pain neuroscience education; physical exercise; primary care; randomized controlled trial
Year: 2020 PMID: 32331323 PMCID: PMC7230486 DOI: 10.3390/jcm9041201
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure A1Pragmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) wheel for this pragmatic trial. For each domain higher scores indicate a more pragmatic approach and lower scores a more explanatory approach.
Figure 1Distribution of the program followed by the experimental group.
Figure 2CONSORT flow diagram. * Initial assessment included initial personal and sociodemographic variables, health-related quality of life (SF-36), catastrophism (PCS: pain catastrophizing scale), kinesiophobia (TSK-11: Tampa Scale for Kinesiophobia-11), central sensitization (CSI: central sensitization inventory), disability (RMDQ: Roland–Morris disability questionnaire), pain intensity (VAS: visual analogue scale), pain areas (McGill maps), and algometry (PPTs: pain pressure thresholds). † Post-intervention assessment satisfaction survey with healthcare received (CSQ-8: client satisfaction questionnaire-8) was added. ‡ The 6-month assessment was the same as the initial assessment.
Characteristics of the recruited sample.
| EG | CG | |
|---|---|---|
| Age (mean ± SD) | 53.02 ± 10.7 | 49.14 ± 12.14 |
| Female (n) | 65 | 71 |
|
| ||
|
| 62 | 57 |
|
| 5 | 5 |
|
| 14 | 15 |
|
| 8 | 4 |
|
| ||
|
| 3.7 | 6.2 |
|
| 33.7 | 35.8 |
|
| 16.9 | 17.3 |
|
| 12.4 | 7.4 |
|
| 14.6 | 17.3 |
|
| 19.1 | 16.0 |
|
| ||
|
| 0.0 | 2.5 |
|
| 40.4 | 51.9 |
|
| 22.5 | 12.3 |
|
| 15.7 | 19.8 |
|
| 21.3 | 13.6 |
|
| ||
| BMI (mean ± SD) | 27.6 ± 4.7 | 26.5 ± 5.0 |
| Pain | ||
|
| 70.8 ± 14.8 | 67.2 ± 14.3 |
|
| 93.13 ± 83.5 | 93.86 ± 84.91 |
|
| 48 | 48 |
| CSP (%) | 100 | 100 |
| Cervical pain | 80.9 | 79.3 |
| Thoracic pain | 65.2 | 50.0 |
| Low back pain | 91.0 | 89.0 |
| Pain in Other Areas (%) | ||
| RUL | 42.7 | 35.4 |
| LUL | 40.4 | 31.7 |
| RLL | 37.1 | 34.1 |
| LLL | 25.8 | 23.2 |
EG: experimental group; CG: control group; BMI: body mass index; Q1: first quartile; Q2: median; Q3: third quartile; CSP: Chronic spinal pain; VAS: visual analogue scale RUL: Right upper limb; LUL: Left upper limb; RLL: Right lower limb right; LLL: left lower limb.
Primary and secondary outcomes.
| Group | Pre | Post | 6 mo | Intra. Dif | Effect Size | Dif. Inter 6 mo | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Physical Function (PF) | EG | 60 ± 18.2 | 80.2 ± 13.4 | 81.4 ± 13.8 | 22 (18.9, 25.2) ** | 1.2 | 18.7 (14.1, 23.4) † |
| CG | 63.1 ± 23.3 | 65.8 ± 22.3 | 65.8 ± 20.9 | 3.3 (−0.1, 6.7) | 0.1 | ||
| Role Physical (RP) | EG | 47.5 ± 26.3 | 77.8 ± 20.7 | 78.2 ± 20.4 | 32.3 (26.4, 38.2) ** | 1.2 | 30.7 (21.6, 39.8) † |
| CG | 56.2 ± 25.7 | 58.1 ± 25.4 | 59.1 ±24.7 | 1.6 (−5.2, 8.5) | 0.1 | ||
| Bodily Pain (BP) | EG | 32.7 ± 17.1 | 75.8 ± 16.5 | 73.1 ± 14.9 | 41 (36.9, 45) ** | 2.4 | 34.9 (28.3, 41.3) † |
| CG | 36.7 ± 19 | 44.2 ± 20.8 | 42.8 ± 23.2 | 6.1 (1, 11.2) * | 0.3 | ||
| Social Functioning (SF) | EG | 60.5 ± 24.1 | 88.1 ± 15.4 | 84.3 ± 18.5 | 24.1 (18.9, 29.3) ** | 1 | 22.7 (14.3, 30.9) † |
| CG | 68.7 ± 24.6 | 71.6 ± 25.3 | 70.7 ± 24.7 | 1.4 (−5.1, 8) | 0.1 | ||
| Mental Heath (MH) | EG | 61.4 ± 18.6 | 77.6 ± 15.7 | 74.1 ± 17.2 | 12.8 (9.3, 16.3) ** | 0.7 | 12.4 (7, 18) † |
| CG | 63.3 ± 19.5 | 63.4 ± 17.3 | 64.4 ± 19 | 0.4 (−3.9, 4.6) | 0 | ||
| Role Emotion (RE) | EG | 74.2 ± 24.7 | 89.2 ± 15.4 | 90.3 ± 15.1 | 16.9 (11.7, 22) ** | 0.7 | 16.7 (9.3, 23.9) † |
| CG | 80.2 ± 21.8 | 80.6 ± 21.4 | 82.6 ± 20.1 | 0.2 (−4.8, 5.3) | 0 | ||
| Vitality (VT) | EG | 40 ± 18.4 | 65.1 ± 17.8 | 59.8 ± 18.5 | 20.3 (16.3, 24.3) ** | 1.1 | 17.4 (10.7, 24.1) † |
| CG | 42.8 ± 20.1 | 44.1 ± 18.4 | 46.8 ± 19.6 | 2.9 (−2.5, 8.3) | 0.1 | ||
| General Health (GH) | EG | 42.4 ± 16.7 | 66.2 ± 16.8 | 65.4 ± 17.7 | 24 (20.4, 27.6) ** | 1.4 | 23.5 (18.1, 28.9) † |
| CG | 48.9 ± 19.9 | 50.7 ± 18.2 | 48.6 ± 20.4 | 0.5 (−3.5, 4.5) | 0 | ||
| Health Transition | EG | 30.1 ± 18.1 | 76.2 ± 15 | 75.9 ± 14.5 | 45.4 (40.5, 50.2) ** | 2.5 | 37.1 (29, 45.1) † |
| CG | 36.1 ± 19.4 | 41.4 ± 22.1 | 43.8 ± 23.6 | 8.3 (1.9, 14.8) | 0.4 | ||
|
| EG | 34.9 ± 7.3 | 47.4 ± 6.9 | 47.4 ± 6.7 | 12.9 (11.4, 14.3) ** | 1.8 | 11.4 (9.1, 13.6) † |
| CG | 37.1 ± 9.3 | 38.9 ± 9 | 38.3 ± 8.5 | 1.5 (−0.2, 3.3) | 0.2 | ||
|
| EG | 44.9 ± 10.1 | 51.7 ± 7.7 | 50 ± 7.9 | 5.1 (3.2, 7.1) ** | 0.5 | 5.2 (2.2, 8.1) † |
| CG | 46.6 ± 10.2 | 46.5 ± 8.8 | 47.3 ± 9.3 | −0.1 (−2.3, 2.1) | 0 | ||
|
| EG | 30.3 ± 8.7 | 15.4 ± 7.3 | 15.5 ± 7.2 | −15 (−16.7, −13.4) ** | −1.7 | −11 (−13.6, −8.4) † |
| CG | 27.9 ± 9.1 | 26.6 ± 9.7 | 24.2 ± 10.3 | −4 (−6, −2.1) ** | −0.4 | ||
| Rumination | EG | 10.5 ± 2.8 | 5.6 ± 2.6 | 5.5 ± 2.6 | −5 (−5.6, −4.5) ** | −1.8 | −3.6 (−4.5, −2.7) † |
| CG | 9.6 ± 3.1 | 9.2 ± 3.2 | 8.2 ± 3.6 | −1.4 (−2.1, −0.7) ** | −0.5 | ||
| Magnification | EG | 6.3 ± 2.3 | 3.1 ± 2 | 3.2 ± 2 | −3.2 (−3.7, −2.7) ** | −1.4 | −2.5 (−3.3, −1.6) † |
| CG | 5.8 ± 2.7 | 5.5 ± 2.8 | 5.3 ± 2.6 | −0.7 (−1.4, −0.1) * | −0.3 | ||
| Helplessness | EG | 13.5 ± 4.6 | 6.7 ± 3.7 | 6.7 ± 3.8 | −6.8 (−7.8, −5.9) ** | −1.5 | −4.9 (−6.4, −3.6) † |
| CG | 12.5 ± 4.6 | 11.9 ± 4.8 | 10.7 ± 5 | −1.9 (−2.8, −0.9) ** | −0.4 | ||
|
| EG | 28.9 ± 6.6 | 17.1 ± 4 | 17.2 ± 4.7 | −12.2 (−13.5, −10.9) ** | −1.8 | −10.6 (−12.4, −8.7) † |
| CG | 27.5 ± 7.1 | 26.1 ± 6.3 | 26.3 ± 7.6 | −1.6 (−3, −0.3) * | −0.2 | ||
|
| EG | 43.4 ± 12.5 | 25.7 ± 10.8 | 25.8 ± 10.5 | −17.7 (−19.3, −16) ** | −1.4 | −16.6 (−19, −14.1) † |
| CG | 38.6 ± 11.7 | 37.7±12.4 | 37.4 ± 13.5 | −1.1 (−2.9, 0.6) | −0.1 | ||
| Disability (RMDC) | EG | 9.2 ± 4.8 | 3.3 ± 3.5 | 3.3 ± 3.8 | −6 (−6.8, −5.2) ** | −1.2 | −5.6 (−6.7, −4.5) † |
| CG | 8 ± 4.7 | 7.6 ± 4.6 | 7.7 ± 4.8 | −0.4 (−1.1, 0.2) | −0.1 | ||
| Pain intensity (VAS) | EG | 74.1 ± 14.5 | 26.7 ± 18 | 27 ± 16.2 | −48.2 (−52.6, −43.8) ** | −3.3 | −40.9 (−46.7, −35.2) † |
| CG | 67.2 ± 14.3 | 58.4 ± 17.7 | 59.7 ± 19.8 | −7.3 (−10.6, −3.9) ** | −0.5 | ||
| Algometry (PPT). P1 | EG | 2.4 ± 1 | 3.8 ± 1.5 | 4.2 ± 1.7 | 1.8 (1.5, 2.2) ** | 1.8 | 1.8 (1.4, 2.2) † |
| CG | 2.5 ± 1 | 2.7 ± 1.1 | 2.5 ± 0.9 | 0 (−0.2, 0.3) | 0 | ||
| Algometry (PPT). P2 | EG | 2.3 ± 0.9 | 3.8 ± 1.5 | 4.1 ± 1.7 | 1.9 (1.6, 2.2) ** | 2.1 | 1.7 (1.3, 2.2) † |
| CG | 2.5 ± 1 | 2.6 ± 1.1 | 2.6 ± 1.1 | 0.2 (−0.1, 0.5) | 0.2 | ||
| Algometry (PPT). P3 | EG | 2.5 ± 1.2 | 4.3 ± 1.6 | 4.9 ± 2 | 2.4 (2, 2.8) ** | 2 | 2.2 (1.7, 2.8) † |
| CG | 2.8 ± 1.2 | 3.1 ± 1.5 | 3 ± 1.4 | 0.2 (−0.1, 0.5) | 0.2 | ||
| Algometry (PPT). P4 | EG | 2.6 ± 1.2 | 4.5 ± 1.8 | 5 ± 2.1 | 2.5 (2, 2.9) ** | 2.1 | 2.3 (1.7, 2.9) † |
| CG | 2.8 ± 1.3 | 3.1 ± 1.5 | 3 ± 1.4 | 0.2(-0.1,0.5) | 0.2 |
Pre: Values before intervention; Post: Values post-intervention (week 11); 6 mo: Values six months; Intra. Dif: Intragroup difference; Inter. Dif.: Intergroup difference; * and ** indicates significant intragroup differences between six months assessment and initial assessment (p < 0.05 and p < 0.001, respectively); indicates significant intergroup differences between six months assessment and initial assessment (p < 0.001).
Figure 3Outcome graphical representation. This figure contains outcomes graphical representation in boxplot. Green colour represent experimental group (EG) and red colour represent control group (CG). First boxplot represents the initial assessment, the second boxplot represents post-intervention assessment and the third the assessment at six months; (A) Boxplot for physical component summary (PCS); (B) Boxplot for mental component summary (MCS); (C) Boxplot for catastrophism outcomes; (D) Boxplot for kinesiophobia outcomes (TSK-11); (E) Boxplot for CSI scores (part A); (F) Boxplot for disability (RMDQ); (G) Boxplot for intensity of pain (VAS; (H) boxplot for PPT outcomes; EG d = X.X: Experimental Group effect size at six months (Cohen’s d); CG d = X.X: Control group effect size at six months. Hollow circles represents outlier values.